Clinical studies suggest that the mechanism of MTMZM in treating eczema may be related to regulating the expression of IL-2, IL-4, IL-10, and γ-IFN; therefore, it can improve the body's immunity and reduce inflammatory response [28]. The gene discussed is IL2; the disease is Eczematoid dermatitis.